Hepatitis C



Hepatitis C Screening in the Primary Care Setting


Condition:   Hepatitis C
Intervention:   Diagnostic Test: Hepatitis C Antibody
Sponsor:   New York Institute of Technology
Completed


Hepatitis c and Vitamin D and Iron Status


Condition:   Hepatitis C
Interventions:   Drug: Sofosbuvir 400 mg;   Drug: Daclatasvir 60 mg/day
Sponsor:   Eman Sayed Hassan Abd Allah
Not yet recruiting


Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma


Condition:   Hepatitis C
Intervention:   Other: oral squamous cell carcinoma
Sponsor:   Cairo University
Not yet recruiting


Hepatitis C Testing in VA Community-Based Outpatient Clinics


Condition:   Hepatitis C
Intervention:   Other: QI
Sponsor:   VA Office of Research and Development
Completed


Study of Oral Treatments for Hepatitis C


Condition:   Chronic Hepatitis C
Interventions:   Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only);   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute;   Merck Sharp & Dohme Corp.;   AbbVie
Recruiting


Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil


Condition:   Hepatitis C Virus
Intervention:  
Sponsor:   Janssen-Cilag Ltd.
Completed


Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4


Condition:   Hepatitis C
Interventions:   Drug: Daclatasvir 60 MG Oral Tablet [Daklinza];   Drug: Sofosbuvir 400 MG Oral Tablet [Sovaldi];   Drug: Ribavirin Oral Product
Sponsors:   Zagazig University;   Cairo University
Not yet recruiting



The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital


Condition:   Hepatitis C
Intervention:   Other: community based hepatitis C care and treatment
Sponsors:   Macfarlane Burnet Institute for Medical Research and Public Health Ltd;   St Vincent's Hospital Melbourne
Recruiting


3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study


Condition:   Hepatitis C, Chronic
Intervention:   Drug: Previous treatment in DEB025 study
Sponsor:   Novartis Pharmaceuticals
Completed


Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients


Condition:   Hepatitis C
Intervention:  
Sponsors:   Prof. Dr. med. Jens Reimer;   Janssen-Cilag G.m.b.H
Active, not recruiting



Undiagnosed Hepatitis C Infection in an Urban Hospital


Condition:   Hepatitis C
Intervention:   Other: Observation only, no intervention
Sponsors:   Temple University;   Janssen Services, LLC
Completed


Multidisciplinary Support Program in Chronic Hepatitis C


Condition:   Hepatitis C, Chronic
Intervention:   Other: Multidisciplinary support program
Sponsor:   Parc de Salut Mar
Completed


Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1


Condition:   Hepatitis C
Interventions:   Drug: Alisporivir;   Drug: Boceprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
Sponsor:   Debiopharm International SA
Terminated


Staged Phase I/II Hepatitis C Prophylactic Vaccine


Condition:   Hepatitis C
Interventions:   Biological: AdCh3NSmut1;   Biological: MVA-NSmut;   Other: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting


A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.


Condition:   Hepatitis C
Interventions:   Drug: GSK2336805 10mg;   Drug: GSK2336805 30mg;   Drug: GSK2236805 100mg;   Drug: GSK2236805 200mg;   Drug: GSK2236805 10mg;   Drug: GSK2236805 dose to be determined up to 100mg;   Drug: GSK2236805 5mg;   Drug: GSK2236805 30mg
Sponsor:   GlaxoSmithKline
Completed


A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy


Condition:   Hepatitis C
Intervention:   Drug: NOV-205
Sponsor:   Cellectar Biosciences, Inc.
Completed


A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)


Condition:   Hepatitis C, Chronic
Interventions:   Drug: Vaniprevir 600 mg b.i.d.;   Drug: Vaniprevir 300 mg b.i.d.;   Drug: Pegylated interferon;   Drug: Ribavirin
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)


Condition:   Hepatitis C, Chronic
Interventions:   Drug: Vaniprevir;   Drug: Pegylated Interferon (Peg-IFN);   Drug: Ribavirin (RBV);   Drug: Placebo (PBO)
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)


Condition:   Hepatitis C, Chronic
Interventions:   Biological: Peginterferon alfa-2b (PegIFN-2b);   Drug: Comparator: Stronger neo minophagen C (SNMC)
Sponsor:   Merck Sharp & Dohme Corp.
Terminated


Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C


Condition:   Hepatitis C
Interventions:   Drug: Infliximab;   Drug: Placebo
Sponsors:   Nizar Zein;   Centocor, Inc.
Completed


Mucomyst for Hepatitis C


Condition:   Hepatitis C
Intervention:   Drug: N-acetylcysteine(Mucomyst)
Sponsors:   VA Office of Research and Development;   West Virginia University
Suspended


Hepatitis C Antiviral Resistance in African-Americans


Condition:   Hepatitis C
Interventions:   Drug: peginterferon alfa-2a;   Drug: Ribavirin
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute on Minority Health and Health Disparities (NIMHD);   National Cancer Institute (NCI);   National Center for Advancing Translational Science (NCATS);   Hoffmann-La Roche
Completed


Immune Response to Hepatitis C Virus


Condition:   Hepatitis C
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Refine Your Search Advanced Search